Developer docs
API playgroundTry for free, no card

Search company profiles

4P-Pharma

Full company profile

uuid0002ia7

Namestring
4P-Pharma
Legal namestring
4P-Pharma
Websiteurl
4p-pharma.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLille, France
HQ citystring
Lille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, drug regeneration therapeutics, disease-modifying drug development, biotech startup studio, pharmaceutical pipeline licensing
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biotechnology / Pharmaceutical drug development
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Development and Licensing
TypeLicensing Royalties
Description

The company develops drug candidates through its SPV model and plans to commercialize through strategic alliances and licensing agreements by territory and therapeutic area

4p-pharma.com
2SPV Equity Value
TypeSubscription Recurring
Description

Creating value through subsidiary companies (4Moving Biotech, 4Living Biotech, Dev4All) with independent funding rounds and growth trajectories

4p-pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Dev4All
Description

R&D booster launched by 4P-Pharma to turn innovative ideas into clinical-stage candidates

4p-pharma.com
Core offering1 text field

4P-Pharma is a clinical-stage biotechnology company that develops first-in-class therapies by regenerating existing drug mechanisms of action for new disease targets. It operates a startup studio model in which therapeutic candidates are sourced through open innovation with academic and AI partners, then advanced in dedicated Single Product Vehicles (SPVs) such as 4Moving Biotech and 4Living Biotech toward clinical proof of concept and eventual out-licensing to big pharma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ≥ 500 candidates screened, ≥ 30 preclinical proof of concept achieved in 10 years of operations
+2 more records
Product overview1 text field

4P-Pharma is a clinical-stage biotech startup studio focused on drug regeneration — developing first-in-class therapies for untreated serious diseases by repurposing existing drug mechanisms. The company operates through Single Product Vehicles (SPVs): 4Moving Biotech (osteoarthritis, 4P004), 4Living Biotech (respiratory/ophthalmology, 4P021/4P020), and Dev4All (R&D booster). The pipeline spans chronic/autoimmune diseases (4P004, 4P025), respiratory diseases (4P021), and ophthalmological conditions (4P020), leveraging AI partnerships for discovery and in-silico clinical trials for acceleration.

Product and service7 records
14Moving Biotech
CategorySubsidiary / SPV biotech entity
Description

Clinical-stage SPV spin-off developing first-in-class disease-modifying osteoarthritis drug (DMOAD) 4P004, a GLP-1 analog with anti-inflammatory, anti-catabolic and anabolic properties for knee osteoarthritis. Aimed at large pharma licensing and clinical collaboration partners.

24Living Biotech
CategorySubsidiary / SPV biotech entity
Description

Wholly-owned SPV spin-off developing 4P021 (CXCR4 antagonist) for acute respiratory distress syndrome (ARDS) and pulmonary complications, and 4P020 for ophthalmological diseases including Stargardt disease and dry AMD. Aimed at clinical collaboration and licensing partners.

3Dev4All
CategoryR&D services / biotech development booster
Description

R&D booster entity offering biotech development services to transform innovative therapeutic ideas into clinical-stage candidates, leveraging 4P-Pharma's R&D engine and CRO expertise. Targets academic institutions, AI biotechs, and other innovators.

44P004
CategoryPipeline asset (osteoarthritis therapeutic)
Description

First-in-class GLP-1 analog intra-articular disease-modifying osteoarthritis drug (DMOAD) showing anti-inflammatory, anti-catabolic and anabolic properties. Developed in collaboration with Prof. Francis Berenbaum's team at St-Antoine's Hospital Paris and SATT Lutech. Currently in Phase 2a INFLAM-MOTION study across Europe and North America. Owned by SPV 4Moving Biotech.

54P025
CategoryPipeline asset (rare liver disease therapeutic)
Description

Drug candidate in discovery stage for the treatment of Primary Sclerosing Cholangitis (PSC), a rare liver condition characterized by inflammation and scarring of bile ducts. Discovered in partnership with Delta4's AI platform.

64P020
CategoryPipeline asset (ophthalmology therapeutic)
Description

First-in-class beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration (dry AMD). Developed in collaboration with Institut de la Vision and SATT Lutech. Owned by SPV 4Living Biotech.

74P021
CategoryPipeline asset (respiratory disease therapeutic)
Description

CXCR4 antagonist for curative treatment of acute respiratory distress syndrome (ARDS) and pulmonary complications. Developed with Prof. Patrick Berger's team at CHU de Bordeaux, INSERM, SATT Aquitaine, and Institut Pasteur de Lille. Owned by SPV 4Living Biotech.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or Integration
Description

Partnership with Delta4, an AI tech company based in Vienna, Austria, to discover and develop a drug candidate for the treatment of Primary Sclerosing Cholangitis (PSC). Delta4 provides AI platform technology for drug discovery.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration with Oncocross, a Korea-based AI tech company, to develop an AI platform-based treatment for systemic sclerosis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Institut de la Vision for development of 4P020 (beta-3 adrenergic receptor agonist) for Stargardt disease and dry AMD.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with SATT Lutech for technology transfer and development of therapeutic candidates including 4P020 and 4P004.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with Institut Pasteur de Lille for research collaboration and hosting of company headquarters.

6Academic Institutions Worldwide
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Open innovation partnerships with worldwide leading academic institutions to source innovative therapeutic assets.

4p-pharma.com
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

French clinical-stage biotech developing therapies for liver diseases including Primary Sclerosing Cholangitis (PSC). Both 4P-Pharma's 4P025 program and Genfit's pipeline target PSC and rare liver conditions, making it a direct comparable for indication overlap and clinical-stage biotech dynamics.

TypeDirect peer
Description

Clinical-stage biotech developing first-in-class disease-modifying osteoarthritis drugs (DMOADs), most notably lorecivivint (CLK/DYRK1 inhibitor). Direct comparator to 4P004 given shared focus on disease modification rather than symptomatic relief in knee OA.

TypeDirect peer
Description

Developed obeticholic acid for primary sclerosing cholangitis and NASH, making it the most prominent historical PSC drug developer. Highly comparable to 4P025's PSC program in target indication and clinical development approach.

TypeDirect peer
Description

Clinical-stage biotech focused on liver and inflammatory diseases, including therapies for PSC and primary biliary cholangitis (PBC). Comparable to 4P-Pharma's 4Living Biotech SPV in rare disease/liver focus and clinical-stage profile.

TypeBroad incumbent
Description

Belgian-Dutch clinical-stage biotech with historical programs in osteoarthritis and immunology, including JAK inhibitors and other inflammation targets. Broader portfolio than 4P-Pharma but historically a direct competitor in OA drug development.

TypeEmerging player
Description

Clinical-stage biotech developing a single-asset (bradykinin B2 receptor antagonist) for hereditary angioedema with focused, asset-centric structure similar to 4P-Pharma's SPV model. Comparable as a focused clinical-stage company leveraging deep mechanism-of-action expertise.

TypeEmerging player
Description

Danish biotech developing biomarker-driven diagnostics and DMOAD candidates for osteoarthritis and musculoskeletal diseases. Direct adjacency to 4P004's disease area and similar clinical-stage focus on novel OA mechanisms.

TypeBroad incumbent
Description

Mid-size French pharmaceutical company with significant rare disease and specialty care franchises. Relevant as a French incumbent peer and potential strategic acquirer of 4P-Pharma's SPV assets in rare/specialty indications.

TypeOthers
Description

French healthtech applying in-silico clinical trial simulation and AI-driven trial design — closely aligned with 4P-Pharma's stated use of in-silico clinical trial technology and partnerships (QuantHealth, Delta4).

TypeOthers
Description

French AI company specializing in generative chemistry and small-molecule drug design. Comparable ecosystem player in the AI-for-drug-discovery space that 4P-Pharma leverages via Delta4, Oncocross, and QuantHealth partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4P-Pharma

Clinical-stage biotechnology / Pharmaceutical drug development4p-pharma.com

4P-Pharma firmographics

Firmographics
Name
4P-Pharma
Legal name
4P-Pharma
Website
https://4p-pharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

4P-Pharma industry classification

Industry
Product category
Clinical-stage biotechnology / Pharmaceutical drug development
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Clinical-stage biotechnology
  • Drug regeneration therapeutics
  • Disease-modifying drug development
  • Biotech startup studio
  • Pharmaceutical pipeline licensing

Where 4P-Pharma is headquartered

Location

Headquarters

HQ city
Lille
HQ country
France
HQ region
Europe

Offices2 records

Markets served

4P-Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Therapeutic Development and Licensing: The company develops drug candidates through its SPV model and plans to commercialize through strategic alliances and licensing agreements by territory and therapeutic area
  2. SPV Equity Value: Creating value through subsidiary companies (4Moving Biotech, 4Living Biotech, Dev4All) with independent funding rounds and growth trajectories

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

4P-Pharma product offering

Product offering

Core offering

4P-Pharma is a clinical-stage biotechnology company that develops first-in-class therapies by regenerating existing drug mechanisms of action for new disease targets. It operates a startup studio model in which therapeutic candidates are sourced through open innovation with academic and AI partners, then advanced in dedicated Single Product Vehicles (SPVs) such as 4Moving Biotech and 4Living Biotech toward clinical proof of concept and eventual out-licensing to big pharma.

Product overview

4P-Pharma is a clinical-stage biotech startup studio focused on drug regeneration — developing first-in-class therapies for untreated serious diseases by repurposing existing drug mechanisms. The company operates through Single Product Vehicles (SPVs): 4Moving Biotech (osteoarthritis, 4P004), 4Living Biotech (respiratory/ophthalmology, 4P021/4P020), and Dev4All (R&D booster). The pipeline spans chronic/autoimmune diseases (4P004, 4P025), respiratory diseases (4P021), and ophthalmological conditions (4P020), leveraging AI partnerships for discovery and in-silico clinical trials for acceleration.

Differentiator

Problem solved

Functional benefit

Brands

  • Dev4All: R&D booster launched by 4P-Pharma to turn innovative ideas into clinical-stage candidates

Products and services

  • 4Moving Biotech Clinical-stage SPV spin-off developing first-in-class disease-modifying osteoarthritis drug (DMOAD) 4P004, a GLP-1 analog with anti-inflammatory, anti-catabolic and anabolic properties for knee osteoarthritis. Aimed at large pharma licensing and clinical collaboration partners.
  • 4Living Biotech Wholly-owned SPV spin-off developing 4P021 (CXCR4 antagonist) for acute respiratory distress syndrome (ARDS) and pulmonary complications, and 4P020 for ophthalmological diseases including Stargardt disease and dry AMD. Aimed at clinical collaboration and licensing partners.
  • Dev4All R&D booster entity offering biotech development services to transform innovative therapeutic ideas into clinical-stage candidates, leveraging 4P-Pharma's R&D engine and CRO expertise. Targets academic institutions, AI biotechs, and other innovators.
  • 4P004 First-in-class GLP-1 analog intra-articular disease-modifying osteoarthritis drug (DMOAD) showing anti-inflammatory, anti-catabolic and anabolic properties. Developed in collaboration with Prof. Francis Berenbaum's team at St-Antoine's Hospital Paris and SATT Lutech. Currently in Phase 2a INFLAM-MOTION study across Europe and North America. Owned by SPV 4Moving Biotech.
  • 4P025 Drug candidate in discovery stage for the treatment of Primary Sclerosing Cholangitis (PSC), a rare liver condition characterized by inflammation and scarring of bile ducts. Discovered in partnership with Delta4's AI platform.
  • 4P020 First-in-class beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration (dry AMD). Developed in collaboration with Institut de la Vision and SATT Lutech. Owned by SPV 4Living Biotech.
  • 4P021 CXCR4 antagonist for curative treatment of acute respiratory distress syndrome (ARDS) and pulmonary complications. Developed with Prof. Patrick Berger's team at CHU de Bordeaux, INSERM, SATT Aquitaine, and Institut Pasteur de Lille. Owned by SPV 4Living Biotech.

Quantifiable outcome

  • ≥ 500 candidates screened, ≥ 30 preclinical proof of concept achieved in 10 years of operations
  • +2 more outcomes

Companies that use 4P-Pharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

4P-Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

4P-Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Delta4coreTechnology or IntegrationPartnership with Delta4, an AI tech company based in Vienna, Austria, to discover and develop a drug candidate for the treatment of Primary Sclerosing Cholangitis (PSC). Delta4 provides AI platform technology for drug discovery.
  • OncocrosscoreTechnology or IntegrationCollaboration with Oncocross, a Korea-based AI tech company, to develop an AI platform-based treatment for systemic sclerosis.
  • Institut de la VisioncoreStrategic or Co-development PartnerPartnership with Institut de la Vision for development of 4P020 (beta-3 adrenergic receptor agonist) for Stargardt disease and dry AMD.
  • SATT LutechcoreStrategic or Co-development PartnerPartnership with SATT Lutech for technology transfer and development of therapeutic candidates including 4P020 and 4P004.
  • Pasteur LillecoreStrategic or Co-development PartnerStrategic partnership with Institut Pasteur de Lille for research collaboration and hosting of company headquarters.
  • Academic Institutions WorldwidecoreStrategic or Co-development PartnerOpen innovation partnerships with worldwide leading academic institutions to source innovative therapeutic assets.

Scale indicators6 records

Recent moves2 records

4P-Pharma competitors and assessment

Company assessment

Direct peers

  • Genfit: French clinical-stage biotech developing therapies for liver diseases including Primary Sclerosing Cholangitis (PSC). Both 4P-Pharma's 4P025 program and Genfit's pipeline target PSC and rare liver conditions, making it a direct comparable for indication overlap and clinical-stage biotech dynamics.
  • Biosplice (formerly Samumed): Clinical-stage biotech developing first-in-class disease-modifying osteoarthritis drugs (DMOADs), most notably lorecivivint (CLK/DYRK1 inhibitor). Direct comparator to 4P004 given shared focus on disease modification rather than symptomatic relief in knee OA.
  • Intercept Pharmaceuticals: Developed obeticholic acid for primary sclerosing cholangitis and NASH, making it the most prominent historical PSC drug developer. Highly comparable to 4P025's PSC program in target indication and clinical development approach.
  • CymaBay Therapeutics: Clinical-stage biotech focused on liver and inflammatory diseases, including therapies for PSC and primary biliary cholangitis (PBC). Comparable to 4P-Pharma's 4Living Biotech SPV in rare disease/liver focus and clinical-stage profile.

Broad incumbents

  • Galapagos NV: Belgian-Dutch clinical-stage biotech with historical programs in osteoarthritis and immunology, including JAK inhibitors and other inflammation targets. Broader portfolio than 4P-Pharma but historically a direct competitor in OA drug development.
  • Ipsen: Mid-size French pharmaceutical company with significant rare disease and specialty care franchises. Relevant as a French incumbent peer and potential strategic acquirer of 4P-Pharma's SPV assets in rare/specialty indications.

Emerging players

  • Pharvaris: Clinical-stage biotech developing a single-asset (bradykinin B2 receptor antagonist) for hereditary angioedema with focused, asset-centric structure similar to 4P-Pharma's SPV model. Comparable as a focused clinical-stage company leveraging deep mechanism-of-action expertise.
  • Nordic Bioscience: Danish biotech developing biomarker-driven diagnostics and DMOAD candidates for osteoarthritis and musculoskeletal diseases. Direct adjacency to 4P004's disease area and similar clinical-stage focus on novel OA mechanisms.

Others

  • Novadiscovery: French healthtech applying in-silico clinical trial simulation and AI-driven trial design — closely aligned with 4P-Pharma's stated use of in-silico clinical trial technology and partnerships (QuantHealth, Delta4).
  • Iktos: French AI company specializing in generative chemistry and small-molecule drug design. Comparable ecosystem player in the AI-for-drug-discovery space that 4P-Pharma leverages via Delta4, Oncocross, and QuantHealth partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

4P-Pharma social profiles

Digital presence

4P-Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4P-Pharma leadership team

Management profile

Number of profiles

Profiles14 records

4P-Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

4P-Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4P-Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4P-Pharma

What does 4P-Pharma do?

4P-Pharma is a clinical-stage biotechnology company that develops first-in-class therapies by regenerating existing drug mechanisms of action for new disease targets. It operates a startup studio model in which therapeutic candidates are sourced through open innovation with academic and AI partners, then advanced in dedicated Single Product Vehicles (SPVs) such as 4Moving Biotech and 4Living Biotech toward clinical proof of concept and eventual out-licensing to big pharma.

Is 4P-Pharma a public or private company?

4P-Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was 4P-Pharma founded?

4P-Pharma was founded in 2014. It employs 11 to 50 people.

Where is 4P-Pharma based?

4P-Pharma is headquartered in Lille, France, in the Europe region.

How does 4P-Pharma make money?

Two revenue lines are on record. Therapeutic Development and Licensing is the primary driver. The others are SPV Equity Value.

Who are 4P-Pharma's main competitors?

Direct peers on record are Genfit, Biosplice (formerly Samumed), Intercept Pharmaceuticals and CymaBay Therapeutics. Broad incumbents are Galapagos NV and Ipsen. Emerging players are Pharvaris and Nordic Bioscience. Others are Novadiscovery and Iktos.

Does 4P-Pharma have an API?

No public API is recorded for 4P-Pharma.

What industry is 4P-Pharma in?

4P-Pharma's product category is Clinical-stage biotechnology / Pharmaceutical drug development. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyEurope’s distinct biotech venture studio modelEuropean biotech venture studios are emerging as a minority formation model, with AQYLA BioVentures and 4P-Pharma exemplifying internal target origination and risk compartmentalization. AQYLA's first programme, STARLIGHT Therapeutics, secured €1.8mn in seed funding, while 4P-Pharma uses a hybrid structure to isolate program-specific risks. The European model is expected to evolve with its own strengths, distinct from the U.S. hub-and-spoke system.Pulse 2.04P-Pharma: €15 Million Raised To Develop Curative Therapies For Untreated Serious Diseases4P-Pharma, a clinical-stage startup studio based in France, has secured €15 million in its second funding closing from private investors to develop curative therapies for untreated serious diseases. This capital injection supports the company's drug regeneration model and provides financial stability for external growth opportunities through M&A and licensing. The funding reflects investor confidence in the company's progress as it moves two of its SPVs into Phase 2 clinical development.FinSMEs4P-Pharma Raises €15M in Second Funding4P-Pharma, a French clinical-stage biotech, raised €15M in second funding. The company will use the funds to deploy its drug regeneration model and pursue M&A and licensing-in opportunities. It aims to accelerate its startup studio model toward commercialization.MaddynessBiotech : 4P-Pharma, spécialiste de la régénération de médicaments, lève 15 millions d’eurosFrench biotech company 4P-Pharma has closed a funding round of 15 million euros, bringing its total capital raised to 20 million euros since its inception. The company intends to use these funds for external growth through acquisitions and licensing agreements to develop therapies for serious unmet medical needs. This financing supports the startup's strategy of repurposing existing molecules into new treatments for conditions such as arthritis and macular degeneration.4P-Pharma4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing4P-Pharma announced the successful completion of its second closing, securing €15 million in capital from private investors. This funding supports the company's drug regeneration model and provides financial stability for operational agility and external growth opportunities through M&A. The investment reflects renewed shareholder confidence as the company advances two first-in-class Single Product Vehicles into Phase 2 clinical development.BioSpace4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing4P-Pharma, a clinical-stage biotechnology company based in Lille, has announced the successful securing of a total capital of €15 million in its second closing with participation from private investors. This funding will support the company's drug regeneration model aimed at developing first-in-class therapies for untreated serious diseases and enhance operational agility through M&A and licensing opportunities. The investment reflects continued trust from shareholders in 4P-Pharma's growth and potential to transform scientific advancements into successful medical solutions.Business Wire Blog4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing4P-Pharma secured €15 million in a second funding round from private investors. The capital will support Phase 2 clinical development of two SPVs and enable M&A and licensing-in opportunities. The company aims to accelerate its drug regeneration model toward commercialization.Business Wire BlogJérôme Vailland Joins 4P-Pharma as Chief Financial OfficerJérôme Vailland has been appointed Chief Financial Officer of 4P-Pharma, a clinical-stage biotech in Lille. He previously served as CFO at Horama and a biotech listed on Euronext Paris. Vailland will support the company's growth, with two drug candidates prepared for Phase II trials.